Home Cart Sign in  
Chemical Structure| 50264-69-2 Chemical Structure| 50264-69-2

Structure of Lonidamine
CAS No.: 50264-69-2

Chemical Structure| 50264-69-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Lonidamine is an inactivator of hexokinase.

Synonyms: AF-1890; Diclondazolic Acid; Doridamina

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Lonidamine

CAS No. :50264-69-2
Formula : C15H10Cl2N2O2
M.W : 321.16
SMILES Code : O=C(C1=NN(CC2=CC=C(Cl)C=C2Cl)C3=C1C=CC=C3)O
Synonyms :
AF-1890; Diclondazolic Acid; Doridamina
MDL No. :MFCD00866285
InChI Key :WDRYRZXSPDWGEB-UHFFFAOYSA-N
Pubchem ID :39562

Safety of Lonidamine

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
4T1 cells 0.1 mg/mL 12 hours Evaluate the photothermal therapeutic effect of BTN@LND NPs on 4T1 cells, results showed that BTN@LND + L group caused over 95% cell death after 1064 nm laser irradiation PMC11007887
LM3 cells 15 µg/mL 12 hours To evaluate the inhibitory effect of LND on glycolysis, the results showed that LND significantly reduced extracellular lactate levels, indicating that LND effectively inhibited glycolysis. PMC10724989
MDA-MB-231 cells 40 μg/mL 24 hours To evaluate the apoptosis-inducing effect of LND-PLGA/TPS/DSSR NPs on MDA-MB-231 cells, the results showed that LND-PLGA/TPS/DSSR NPs significantly increased the proportion of early and late apoptotic cells. PMC10378575
LM3 cells 15 µg/mL 24 hours To evaluate the inhibitory effect of LND on HK activity, the results showed that LND significantly reduced intracellular HK levels, indicating a significant inhibitory effect of LND on HK activity. PMC10724989
Bone marrow-derived macrophages (BMDMs) 200 μM 30 minutes LND inhibited NLRP3 inflammasome activation, reducing caspase-1 and IL-1β secretion. PMC9798610
J774A.1 cells 200 μM 30 minutes LND inhibited NLRP3 inflammasome activation, reducing caspase-1 and IL-1β secretion. PMC9798610
LM3 cells 15 µg/mL 4 hours To evaluate the effect of LND on intracellular GSH levels, the results showed that LND significantly reduced intracellular GSH levels. PMC10724989
HCT 116 50 μM 48 h Lonidamine potentiated the oncolytic effect and increased the infection rate of M1 virus. PMC7607643
HCT-8 50 μM 48 h Lonidamine potentiated the oncolytic effect and increased the infection rate of M1 virus. PMC7607643

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
BALB/c mice 4T1 subcutaneous tumor model Intravenous injection 2.0 mg/mL Single injection, laser irradiation after 24 hours Evaluate the anti-tumor effect of BTN@LND NPs in the 4T1 subcutaneous tumor model, results showed that BTN@LND + L group significantly inhibited tumor growth with only a 1.9-fold increase in tumor volume after 1064 nm laser irradiation PMC11007887
C57BL/6 mice LPS-induced sepsis model Intraperitoneal injection 40 mg/kg and 60 mg/kg Single injection LND significantly alleviated the inflammatory response in the LPS-induced sepsis model, reducing serum levels of IL-1β and IL-18. PMC9798610
BALB/c Nude mice TNBC MDA-MB-231 xenograft model Intravenous injection 4 mg/kg Every other day for 18 days To evaluate the anti-tumor activity of LND-PLGA/TPS/DSSR NPs in the TNBC MDA-MB-231 xenograft model, the results showed that LND-PLGA/TPS/DSSR NPs significantly inhibited tumor growth and reduced the toxicity of LND. PMC10378575
BALB/c Nude mice LM3 subcutaneous xenograft tumor models Tail vein injection 15 µg/mL Injected at days 1, 3 and 5, lasted for 18 days To evaluate the effect of LND on tumor hypoxia, the results showed that LND significantly relieved tumor hypoxia. In addition, LND significantly reduced HSP90 expression in tumor tissues, enhancing the efficacy of photothermal therapy. PMC10724989
BALB/c-nu/nu mice HCT 116 tumor xenograft model Intraperitoneal injection 10 mg/kg Once daily for 5 days Lonidamine in combination with M1 virus significantly inhibited tumor growth without affecting mouse body weight. PMC7607643

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00435448 Benign Prostatic Hyperplasia|E... More >>nlarged Prostate Less << PHASE3 TERMINATED 2025-12-06 Vivantes Klinikum am Urban, Kl... More >>inik für Urologie, Berlin, 10967, Germany|ClinPharm International GmbH & Co KG--Chemnitz, Chemnitz, 09120, Germany|ClinPharm International GmbH & Co KG--Dresden, Dresden, 01067, Germany|niversit?tsklinikum Carl Gustav Carus, Klinik und Poliklinik für Urologie, Dresden, 01307, Germany|Gemeinschaftspraxis Jacobi - Hellmis, Duisburg, 47179, Germany|ClinPharm International GmbH & Co KG--Frankfurt/Main, Frankfurt, 60596, Germany|ClinPharm International GmbH & Co KG--Gorlitz, Gorlitz, 02826, Germany|Universit?tsklinikum Hamburg-Eppendorf, Klinik und Poliklinik für Urologie, Hamburg, 20246, Germany|Universit?tsklinikum Schleswig-Holstein, Campus Kiel, Klinik für Urologie und Kinderurologie, Kiel, 24105, Germany|Universit?tsklinik K?ln, Klinik und Poliklinik für Urologie, K?ln, 50924, Germany|ClinPharm International GmbH & Co KG--Leipzig, Leipzig, 04229, Germany|ClinPharm International GmbH & Co KG--Magdeburg, Magdeburg, 39104, Germany|Urologische Universit?tsklinik, Klinikum Mannheim gGmbH, Fakult?t für Klinische Medizin Mannheim, Mannheim, 68135, Germany|Klinik für Urologie und Kinderurologie, Klinikum Marburg, Marburg, 35033, Germany|Klinikum der Universit?t München, Urologische Klinik und Poliklinik, München, 81377, Germany|Urologische Klinik und Poliklinik der Technischen Universit?t München, Klinikum Rechts der Isar, München, 81675, Germany|Urologische Klinik, Klinikum Landkreis Neumarkt i.d.Obf., Neumarkt, 92318, Germany|Klinik für Urologie, Eberhard-Karls-Universit?t Tübingen, Tubingen, 72076, Germany|Wuppertaler Gemeinschaftspraxis für Dermatologie, Gyn?kologie und Urologie, Wuppertal, 42103, Germany|Károlyi Sándor Hospital, Budapest, 1047, Hungary|Semmelweis University, Budapest, 1082, Hungary|F?városi ?nkormányzat Jahn Ferenc Dél-Pesti Kórház, Budapest, 1204, Hungary|Clinic of Urology, Debrecen, 4012, Hungary|Dombóvári Szt. Lukács Egészségügyi K?zhasznú, Dombóvár, 7200, Hungary|Petz Aladár County Hospital, Gyor, 9024, Hungary|Kaposi Mór County Hospital, Kaposvar, 7400, Hungary|Nagykanizsa Megyei Jogú Város Hospital, Nagykanizsa, 8800, Hungary|Gróf Esterházy Kórház, Papa, 8500, Hungary|Dr. Bugyi István Hospital, Szentes, 6600, Hungary|Saint Bobála Hospital, Tatabánya, 2800, Hungary|A.O. Policlinico di Bari, Clinica Urologica I, Bari, 70124, Italy|A.O. Policlinico di Bari, Clinica Urologica, Bari, 70124, Italy|Ospedale S.Annunziata, Unità Operativa di Urologia, Firenze, 50011, Italy|Università di Genova Ospedale S. Martino, Reparto Urologia, Genova, 16132, Italy|Ospedale S.Paolo, Cattedra di Urologia, Milano, 20142, Italy|Università Federico II, Clinica Urologica Edificio 5, Napoli, 80131, Italy|Azienda Ospedaliera S.Luigi di Orbassano, Reparto di urologia universitaria, Orbassano, 10043, Italy|Azienda Ospedaliera, Dipartimento di Urologia, Padova, 35128, Italy|A.O. Pliclinico Paolo Giaccone, U.O. Urologia con Litotrissia Extracorporea, Palermo, 90129, Italy|Azienda Ospedaliera Pisana, Dipartimento di Urologia 1, Pisa, 56126, Italy|Policlinico Sassarese, Istituto di Clinica Urologica, Sassari, 07100, Italy|Ospedale Maggiore S.Giovanni Battista, Istituto di Urologia, Torino, 10126, Italy|Ospedale S.Giovanni Bosco, Dipartimento di Urologia, Torino, 10154, Italy|Klinika Urologii AM w Bia?ymstoku, Bialystok, 15-276, Poland|Wojewódzki Szpital Specjalistyczny nr 4, Bytom, 41-902, Poland|Gabinet Urologiczny, Gdańsk, 80-210, Poland|Specjalistyczna Praktyka Lekarska, Katowice, 40-086, Poland|Szpital Specjalistyczny Oddzial Urologii, Koscierzyna, 83-400, Poland|"Specjalista" Spó?ka z o. o., Kutno, 99-300, Poland|Wojewódzki Szpital,Oddzia? i Poradnia Urologiczna, Legnica, 59-220, Poland|Szpital Im. Kardyna?a Stefana Wyszyńskiego, Oddzia? Urologii, Lublin, 20-718, Poland|Wojewódzki Szpital Specjalistyczny im. Janusza Korczaka, Oddzia? Urologii, Slupsk, 76-200, Poland|Katedra i Klinika Urologii Pomorskiej Akademii Medycznej, Szczecin, 70-111, Poland|Szpital Bielański, Oddzia? Urologii, Warszawa, 01-908, Poland|Szpital Specjalistyczny, Oddzia? Urologii, Wejherowo, 84-200, Poland|Katedra i Klinika Urologii AM we Wroc?awiu, Wroclaw, 50-043, Poland|Katedra i Klinika Urologii ?l?skiej Akademii Medycznej, Zabrze, 41-800, Poland|NZOZ Lekarze Urolodzy, Marek Rozniecki i Partnerzy, ?ask, 98-100, Poland Less <<
NCT00237536 Benign Prostatic Hyperplasia PHASE2 TERMINATED 2025-08-06 Advanced Clinical Therapeutics... More >>, Tucson, Arizona, 85712, United States|Chris B. Threatt, MD Inc., Atherton, California, 94027, United States|Urological Sciences Research Foundation, Culver City, California, 90232, United States|Atlantic Urological Medical Group, Long Beach, California, 90806, United States|California Professional Research, Newport Beach, California, 92660, United States|San Diego Uro-Research, San Diego, California, 92103, United States|Stanford University Hospital, Stanford, California, 94305, United States|Urology Research Options, Aurora, Colorado, 80012, United States|Connecticut Clinical Research Center Urology Specialists, Waterbury, Connecticut, 06708, United States|South Florida Medical Research, Aventura, Florida, 33180, United States|Tampa Bay Medical Research, Clearwater, Florida, 33761, United States|Florida Healthcare Research, Ocala, Florida, 34474, United States|Midwest Prostate & Urology Health Center, Chicago, Illinois, 60640, United States|Specialty Care Research, Peoria, Illinois, 61614, United States|Northeast Indiana research, LLC, Fort Wayne, Indiana, 46825, United States|Metropolitan Urology, Jeffersonville, Indiana, 47130, United States|Werner, Murdock & Francis, PA, Urology Associates, Greenbelt, Maryland, 20770, United States|Sheldon J. Freedman, MD Ltd., Las Vegas, Nevada, 89109, United States|Delaware Valley Clinical Research, Cherry Hill, New Jersey, 08003, United States|Lawrenceville Urology, Lawrenceville, New Jersey, 08648, United States|Urology Healthcare Associates, Westampton, New Jersey, 08060, United States|Accumed Research Associates, Garden City, New York, 11530, United States|New York University School of Medicine, New York, New York, 10016, United States|Weill Medical College of Cornell University, New York, New York, 10021, United States|Radiant Research. Columbus, Columbus, Ohio, 43212, United States|Urological Associates of Lancaster, Lancaster, Pennsylvania, 17604, United States|State College Urologic Associates, State College, Pennsylvania, 16801, United States|University Urological Research Institute, Providence, Rhode Island, 02904, United States|Radiant Research, Greer, Greer, South Carolina, 29651, United States|UT Southwestern Medical Center at Dallas, Dept of Urology, Dallas, Texas, 75390, United States|Accelovance, Houston, Texas, 77024, United States|Baylor College of Medicine, Scott Department of Urology, Houston, Texas, 77030, United States|Urology San Antonio Research, San Antonio, Texas, 78229, United States|Integrity Medical Research, LLC, Mountlake Terrace, Washington, 98043, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.11mL

0.62mL

0.31mL

15.57mL

3.11mL

1.56mL

31.14mL

6.23mL

3.11mL

References

 

Historical Records

Categories